3 Cannabis Stocks That Could Soar After Marijuana Rescheduling

Source The Motley Fool

Key Points

  • Marijuana rescheduling can result in significant tax savings for multi-state operators (MSOs) in the U.S.

  • Three of the largest MSOs are Curaleaf Holdings, Green Thumb Industries, and Trulieve Cannabis.

  • These are among the better-run cannabis companies in the entire industry, and they could be among the biggest winners from marijuana reform.

  • 10 stocks we like better than Curaleaf ›

The U.S. government recently announced it has rescheduled many medical marijuana products as Schedule III substances (down from Schedule I) and would also be looking at doing the same for recreational pot. For the cannabis industry, it marks a huge milestone. While it's not full-blown legalization or anything close to it, it's still significant progress. And for marijuana companies operating in the U.S., the change also means they'll be able to claim more expenses when filing their tax returns.

As a result, the main benefit from rescheduling will flow through to multi-state operations (MSOs). Three marijuana stocks that may have tremendous upside from rescheduling are Curaleaf Holdings (OTC: CURLF), Green Thumb Industries (OTC: GTBIF), and Trulieve Cannabis (OTC: TCNNF).

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

Investor looking at stocks on a tablet.

Image source: Getty Images.

Curaleaf Holdings

One of the largest MSOs in the country is Curaleaf Holdings. It says it has "unparalleled reach across the United States," with a retail presence in 15 states and 159 locations as of Dec. 31, 2025. In addition, the company has also been expanding internationally into key markets such as Germany and the U.K., and plans to expand to Spain, France, and Turkey in the near future. It's a growth machine that looks to take advantage of opportunities in the marijuana industry.

Last year, the company generated nearly $1.3 billion in revenue, which was down 5% from the previous year. Cannabis companies have been struggling to find new growth opportunities, but as the industry expands, especially if greater reform is on the horizon, Curaleaf can be among the biggest winners from reform due to its vast presence and appetite for growth. For the 2025 fiscal year, the company estimates that it would have saved around $116 million on taxes related to 280e if rescheduling were implemented.

Shares of Curaleaf have spiked on rescheduling news, and they are now up 34% since the start of the year.

Green Thumb Industries

Another leading cannabis company is Green Thumb Industries, which has a comparable presence to Curaleaf. Green Thumb operates in 14 states and has 113 retail stores (as of March 6). Revenue has been rising, although its growth rate has slowed significantly in recent years due to a lack of new opportunities. But like Curaleaf, future reform could change that, and greater profitability may enable it to pursue more expansion.

In 2025, the company generated close to $1.2 billion in revenue, which was an increase of 3% from the previous year. What's noteworthy about Green Thumb is that, unlike many of its peers, its operations are already profitable. Last year, it generated net income of $114 million, which was up from $73 million in the previous year.

Earlier this year, CEO Ben Kovler estimated that Green Thumb would generate as much as $60 million per year in extra free cash flow as a result of rescheduling. Free cash can be critical in the industry to enable a cannabis giant such as Green Thumb to target more markets in the U.S., to help grow its sales.

Shares of Green Thumb have been rising in recent days, though on a year-to-date basis, the stock is up around just 3%. It could, however, have much more upside in the long run.

Trulieve Cannabis

Florida-based Trulieve Cannabis is another company poised to benefit significantly from rescheduling. It had 233 retail locations as of the end of 2025. However, the bulk of those are in its home state of Florida. It's not as diversified as the other companies on this list, but Trulieve is still a huge MSO and one that can benefit significantly from marijuana reform.

In 2025, it generated approximately $1.2 billion in revenue, which was virtually unchanged from the previous year. Although it posted a loss of $117 million for the year, it was profitable before taxes, with a pre-tax profit of nearly $92 million; its $208 provision for income taxes wiped that out entirely. Trulieve could stand to benefit significantly from rescheduling and a lower tax bill.

It's another pot stock that's been rallying in recent days, and it's now up more than 7% since the start of 2026. For long-term investors, it could be a compelling option to consider given its potential to rise far higher and expand into more states.

Should you buy stock in Curaleaf right now?

Before you buy stock in Curaleaf, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Curaleaf wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $492,752!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,327,935!*

Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 201% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of April 28, 2026.

David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool recommends Green Thumb Industries. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Bitcoin CME gaps at $35,000, $27,000 and $21,000, which one gets filled first?Prioritize filling the $27,000 gap and even try higher.
Author  FXStreet
Aug 22, 2023
Prioritize filling the $27,000 gap and even try higher.
placeholder
Natural Gas sinks to pivotal level as China’s demand slumpsNatural Gas price (XNG/USD) edges lower and sinks to $2.56 on Monday, extending its losing streak for the fifth day in a row. The move comes on the back of China cutting its Liquified Natural Gas (LNG) imports after prices rose above $3.0 in June. It
Author  FXStreet
Jul 01, 2024
Natural Gas price (XNG/USD) edges lower and sinks to $2.56 on Monday, extending its losing streak for the fifth day in a row. The move comes on the back of China cutting its Liquified Natural Gas (LNG) imports after prices rose above $3.0 in June. It
placeholder
Elon Musk’s xAI and Neuralink Launch New Funding Rounds​Billionaire Elon Musk recently raised funds for his two high-profile tech companies, xAI and Neuralink.
Author  Insights
Jun 03, 2025
​Billionaire Elon Musk recently raised funds for his two high-profile tech companies, xAI and Neuralink.
placeholder
Silver Price Forecast: XAG/USD plummets below $76 as oil price posts fresh weekly highSilver price (XAG/USD) is down almost 2.3% to near $76.00 during the European trading session on Thursday. The white metal faces selling pressure as oil prices extends its winning streak for the third trading day on Thursday.
Author  FXStreet
Apr 23, Thu
Silver price (XAG/USD) is down almost 2.3% to near $76.00 during the European trading session on Thursday. The white metal faces selling pressure as oil prices extends its winning streak for the third trading day on Thursday.
placeholder
Japanese Yen extends the range play against USD; looks to BoJ for fresh impetusThe USD/JPY pair is seen consolidating in a narrow band around mid-159.00s during the Asian session on Tuesday as traders opt to wait for the crucial Bank of Japan (BoJ) before placing fresh directional bets.
Author  FXStreet
14 hours ago
The USD/JPY pair is seen consolidating in a narrow band around mid-159.00s during the Asian session on Tuesday as traders opt to wait for the crucial Bank of Japan (BoJ) before placing fresh directional bets.
goTop
quote